Purchase this article with an account.
Antonio Polito, Laura Bertazzi, Emilia Maggio, Federica Romanelli, Grazia Pertile; Full macular translocation for choroidal neovascularization in age-related macular degeneration: long term results. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4966.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to report the long-term (>3 years) outcomes of full macular translocation (FMT) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration.
we retrospectively reviewed a consecutive series of 137 patients who underwent translocation between 2004 and 2012. We evaluated best-corrected visual acuity (BCVA) obtained before and 1 year and at the most recent follow-up.
The mean (range) follow-up duration was 41 months (range 12-96 months). The mean BCVA values were 1.13, 0.79 and 0.92 logMAR at the baseline, 1 year and most recent visits (p= 0.001). A three-line gain was observed in 67 (49%) and 59 (43%) patients at 1 year and at the last observation, respectively. Fifty-seven (42%) patients achieved a BCVA of 20/100 or better and twenty-two (16%) patients, 20/40 or better at the final visit. In the subset of the cohort followed for 5 or more years, 23 of 45 patients (51%) achieved a BCVA of 20/100 or better at 1 year, but ten of these (45%) lost two lines of vision over the 5-year period mostly due to recurrent CNV. However, a three-line gain was maintained in 29% of patients in this subgroup.
Although the greatest benefit of FMT can be observed at 1 year, when vision significantly improves in half of patients, visual improvement can still be detected at three and five years in one-third of cases.
This PDF is available to Subscribers Only